Pharma Merger Divestitures: Some Buyers Fail To Replace Generic Products

US FTC analysis of merger remedy orders finds that of 42 on-market generic products that required manufacturing transfer, the buyer was unable to continue to sell 15 products.

United States Federal Trade Commission building in Washington, DC

When generic manufacturers are ordered to divest products to win approval of a merger from the US Federal Trade Commission (FTC), there is a chance one of the products may be discontinued.

FTC found more than a dozen instances in which the buyer of a generic product was unable to continue to sell it. The Commission’s Bureaus of Competition and Economics disclosed...

More from Generics

More from Biosimilars & Generics